By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Infectious substance packaging is the process of properly packaging and shipping materials that can cause disease in humans or animals, such as cultures, patient specimens, biological products, medical or clinical wastes, and medical devices or equipment. Infectious substance packaging is important for ensuring the safety of lab personnel, transport workers, and the public, as well as preventing environmental hazards.
Infectious substance packaging follows the guidelines and regulations of the World Health Organization (WHO), the International Air Transport Association (IATA), and other national and international authorities.
Infectious substances are classified into two categories: Category A (infectious substances that are capable of causing permanent disability, life-threatening or fatal disease in humans or animals) and Category B (infectious substances that do not meet the criteria for Category A).
Infectious substance packaging requires the use of a basic triple packaging system, which consists of three layers: a primary receptacle (a leak-proof container that holds the specimen), a secondary packaging (a leak-proof container that encloses and protects the primary receptacle), and an outer packaging (a rigid container that protects its contents from outside influences while in transit).
The packaging must also include appropriate labels, markings, and documentation to indicate the nature and quantity of the material, the sender and receiver information, and any special handling instructions
In 2023, the healthcare industry emerged as the primary consumer of infectious substance packaging, securing a substantial majority of the market share, exceeding 50%. This growth is underpinned by several factors, including the escalating prevalence of infectious diseases, augmented healthcare spending, and a heightened awareness of the critical role played by infectious substance packaging.
Following closely, the pharmaceutical sector claims the second-largest share of the market, standing at over 25% in 2023. The upswing in this sector is attributed to the burgeoning development and manufacturing of novel drugs and vaccines. These endeavors necessitate robust infectious substance packaging to guarantee the integrity and safety of these pharmaceutical products.
The research domain takes the third spot as a significant end-user of infectious substance packaging, contributing to more than 15% of the market share in 2023. This growth is propelled by the expanding scope of research and development activities dedicated to infectious diseases, reflecting an increasing focus on addressing and understanding these critical health concerns.
The Global Infectious Substance Packaging market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Reusable infectious substance packaging is becoming increasingly popular as it is more cost-effective and environmentally friendly than disposable packaging. Manufacturers are developing new reusable packaging solutions that are also easy to clean and disinfect.
Government regulatory requirements and incentives can have a significant impact on the global infectious substance packaging market. For example, regulatory requirements can increase the cost of manufacturing infectious substance packaging, but they can also help to ensure the safety of workers, the public, and the environment.
Government incentives, on the other hand, can help to reduce the cost of developing and bringing new infectious substance packaging solutions to market. This can lead to a wider range of innovative packaging solutions becoming available to customers.
Intelsius, a company that produces BioTherm™, PathoPak™, PathoShield™, and ORCA™ packaging systems for Category A and B substances, which are designed to ensure full compliance and ease of use for transporting samples that require temperature control
Intelsius BioTherm packaging systems ensure that you meet all IATA, ADR, and 49 CFR (DOT) transit rules. These shipping solutions are pre-qualified to ensure sample integrity throughout 24 to 120-hour shipments against Intelsius’ stringent High-Performance Dry Ice temperature, 2-8°C profiles, and 15-25°C profiles. Intelsius Specimen Transport Packaging is used to test and qualify the range.
The PathoPak line is UN approved for Category A shipments and complies with IATA, ADR, and CFR 49 (DOT) transport rules, offering optimal sample protection regardless of specimen categorization. Furthermore, each system has met or exceeded the UN performance testing criteria, allowing any primary container to be transported.
The PathoPak is strong, sturdy, and very protective. It is ergonomically constructed with an identical circumference throughout for ease of packing and removing samples.
This reusable rigid system is a cost-effective alternative for delivering a wide range of primary materials such as blood tubes, specimen containers, swabs, blood collection/transfusion bags, and medical gadgets.
